Opening book details…
Can I read The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites on EtoBox?
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites by Anthony Mato; Chadi Nabhan; Nicole Lamanna; Neil E. Kay; David L. Grinblatt; Christopher R. Flowers; Charles M. Farber; Matthew S. Davids; Arlene S. Swern; Kristen Sullivan; E. Dawn Flick; Sarah M. Gressett Ussery; Mecide Gharibo; Pavel Kiselev; Jeff P. Sharman is a Medicine article available to read on EtoBox.
What is The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites about?
## Abstract Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL Registry, a United States–based multicenter prospective observational cohort study, enrolled 1494 patients between 2010 and 2014 from predominantly community-based settings. Patients were grouped by line of therapy (LOT) at enrollment. With a median follow-up of 46.6 months (range, 0-63.0 months), median overall survival (OS) was not reached in LOT1, 63.0 months (95% confidence interval [CI], 46.0-63.0 months) in LOT2, and 38.0 months (95% CI, 33.0-47.0 months) in LOT≥3. Bendamustine and rituximab (BR; 33.5%); fludarabine, cyclophosphamide, and rituximab (FCR; 21.4%); and rituximab monotherapy (18.5%) were the most common regimens across LOTs. Median event-free survival (EFS) was similar in patients treated with BR (59.0 months) and FCR (55.0 months) in LOT1; median OS was not reached. In multivariable analysis, BR or FCR vs other treatments in LOT1 was associated with improved EFS (hazard ratio [HR], 0.60; P < .0001) and OS (0.67; P = .0162). Using the Kaplan-Meier product limit, ibrutinib vs other treatments improved OS in LOT2 (HR, 0.279; P = .009), LOT3 (0.441; P = .011), and LO
Who reads The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Anthony Mato; Chadi Nabhan; Nicole Lamanna; Neil E. Kay; David L. Grinblatt; Christopher R. Flowers; Charles M. Farber; Matthew S. Davids; Arlene S. Swern; Kristen Sullivan; E. Dawn Flick; Sarah M. Gressett Ussery; Mecide Gharibo; Pavel Kiselev; Jeff P. Sharman
- Publisher
- American Society of Hematology (ISSN 2473-9529)
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)